Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00585195
First received: December 29, 2007
Last updated: November 21, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2019
  Estimated Primary Completion Date: November 2019 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):